10 December 2014Americas

Merck insists on buyout despite generic blow

Pharmaceutical company Merck has said it will press on with an $8.4 billion buyout of Cubist Pharmaceuticals despite a court ruling that could pave the way for a generic version of a lucrative Cubist drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Abbott IP chief: ‘Firms without AI policies scare me’

5 March 2026 The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.

Americas

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

5 March 2026 Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.

Americas

To cite or not to cite: How can we avoid misuse of AI in court?

4 March 2026 With an increase in ‘hallucinated’ case law cited as evidence in courts globally, what can legal practitioners—as well as providers of AI tools and platforms—do to help safeguard against this? Sarah Speight finds out.

More features

Nomination call: Influential Women in IP list closes ahead of International Women’s Day

Abbott IP chief: ‘Firms without AI policies scare me’

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

DWT recruits first-chair trial litigator as latest hire in IP expansion

FisherBroyles opens San Diego office

To cite or not to cite: How can we avoid misuse of AI in court?

Gowling WLG brings in transactions expert with UK and US experience

LSPN Awards 2026 finalists revealed

Merck insists on buyout despite generic blow

More on this story

Editor's picks

Editor's picks

More features